Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Rodriguez-Mogeda, Carla; van Lierop, Zoë Y. G. J.; van der Pol, Susanne M. A.; Coenen, Loet; Hogenboom, Laura; Kamermans, Alwin; Rodriguez, Ernesto; van Horssen, Jack; van Kempen, Zoé L. E.; Uitdehaag, Bernard M. J.; Teunissen, Charlotte E.; Witte, Maarten E.; Killestein, Joep; de Vries, Helga E.

doi:10.1186/s12974-023-02900-z

Journal of Neuroinflammation

Table 2 Antibodies for CyTOF

From: Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Metal	Antigen	Clone	Manufacturer	Concentration (µL) per 100 µL	Cocktail
106Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
110Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
111Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
112Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
113Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
114Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
116Cd	CD45	HI30	Standard BioTools	0.25	Barcoding
89Y	CD45	HI30	Standard BioTools	1	Surface
141Pr	CD235ab	HIR2	Standard BioTools	0.5	Surface
142Nd	CD11a	HI111	Standard BioTools	0.5	Surface
143Nd	CD5	UCHT2	Standard BioTools	1	Surface
144Nd	CD69	FN50	Standard BioTools	0.5	Surface
145Nd	CD16	3G8	Standard BioTools	0.25	Surface
146Nd	IgD	IA6-2	Standard BioTools	0.25	Surface
147Sm	CD20	2H7	Standard BioTools	0.5	Surface
148Nd	IgA	Polyclonal	Standard BioTools	0.5	Surface
149Sm	CD25 (IL-2R)	2A3	Standard BioTools	1	Surface
150Nd	CD138	DL-101	Standard BioTools	0.5	Surface
151Eu	CD14	M5E2	BioLegend	1	Surface
152Sm	CD21	BL13	Standard BioTools	0.5	Surface
153Eu	CD8a	RPA-T8	Standard BioTools	0.0625	Surface
154Sm	CD3	UCHT1	Standard BioTools	0.25	Surface
155Gd	CD45RA	HI100	Standard BioTools	0.25	Surface
156Gd	CD86	IT2.2	Standard BioTools	0.25	Surface
158Gd	CD1d	51.1	BioLegend	1	Surface
159Tb	CD11c	Bu15	Standard BioTools	0.125	Surface
161Dy	PD-1	EH12.2H7	BioLegend	0.375	Surface
163Dy	CD56 (NCAM)	NCAM16.2	Standard BioTools	0.015625	Surface
164Dy	CD166	3A6	Standard BioTools	0.5	Surface
165Ho	CD19	HIB19	Standard BioTools	0.25	Surface
166Er	CD24	ML5	Standard BioTools	1	Surface
167Er	CD38	HIT2	Standard BioTools	0.5	Surface
168Er	CD22	HIB22	Standard BioTools	0.25	Surface
169Tm	CD57	HNK-1	BioLegend	0.125	Surface
170Er	CD54	HA58	Standard BioTools	0.125	Surface
171Yb	CD162	KPL-1	BioLegend	0.125	Surface
172Yb	IgM	MHM-88	Standard BioTools	0.125	Surface
173Yb	HLA-DR	L243	Standard BioTools	0.5	Surface
174Yb	CD49d	9F10	Standard BioTools	0.125	Surface
175Lu	CD27	O323	BioLegend	0.25	Surface
176Yb	CD4	RPA-T4	Standard BioTools	0.25	Surface
209Bi	CD11b (Mac-1)	ICRF44	Standard BioTools	0.5	Surface
160Gd	Tbet	4B10	Standard BioTools	0.75	Nuclear
162Dy	FoxP3	PCH101	Standard BioTools	1	Nuclear

Back to article page

ISSN: 1742-2094

Contact us

Submission enquiries: journalsubmissions@springernature.com